IOP-lowering effect with the iStent inject® in POAG eyes with or without history of previous ocular surgery

Session Details

Session Title: Microinvasive Glaucoma Surgery

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 14:00

Venue: Free Paper Forum: Podium 4

First Author: : F.Rüfer GERMANY

Co Author(s): :    M. Dabiri   B. Alokla   M. Matthäi   D. Holland                    

Abstract Details

Purpose:

To assess the IOP-lowering effect of iStent inject® used as either a standalone or combination procedure in POAG eyes with/without history of previous ocular surgery.

Setting:

Single center, single surgeon study, NordBLICK Eye Clinic Bellevue, Kiel, Germany

Methods:

196 eyes of 125 patients with POAG aged 68±11 years were included in the cohort. The IOP and hypotensive medication usage was assessed preoperatively and postoperatively to 12 months. Six phakic eyes underwent standalone iStent inject implantation (PhSTA), 136 phakic eyes underwent combined cataract surgery and stent implantation (PhKOM), 38 pseudophakic eyes without previous ocular surgery underwent standalone stent implantation (PsPh), and 16 pseudophakic eyes who had undergone previous ocular surgery with conjunctival involvement had standalone stent implantation (PsPh+). This final group of 16 eyes comprised 11 eyes with previous trabeculectomy and 5 eyes with previous pars plana vitrectomy.

Results:

Mean IOP (mmHg) of the collective group at 12 months postoperatively (preoperative values in brackets) was 15.4±3.3 (18.7±3.7) and for subgroups: PhSTA 16.3±1.2 (18.5±2.1), PhKOM 15.2±2.9 (19.0±3.8), PsPh 15.8±4.1 (17.8±3.4), and PsPh+ 15.5±3.8 (18.3±3.3). This represents a 17% reduction in IOP in the collective group and ranged from 12-20% reduction depending on the subgroup. In the collective group, mean number of medication at 12 months (preoperative in brackets) was 1.0 (2.0) and in subgroups PhSTA 1.8 (1.3), PhKOM 0.9 (2.0) PsPh 1.1 (2.3), and PsPh+ 1.6 (1.8). A favorable safety profile was observed without significant intraoperative or postoperative complications.

Conclusions:

This study shows the IOP-lowering effect following iStent inject® implantation in POAG eyes with combined cataract surgery, in phakic eyes undergoing a standalone procedure, in pseudophakic eyes and also in pseudophakic eyes with a history of previous surgery. These results demonstrate the effectiveness of the iStent inject in IOP lowering and medication reduction in patients with POAG with and without concomitant cataract surgery and history of previous ocular surgery. Consistent with current literature, a high safety profile was observed.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented